Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Postow

Showing results (71-80 of 212) with videos related to

Pageof 22
Sort By:
Cell Reports Methods|September 6, 2023
A topic modeling approach reveals the dynamic T cell composition of peripheral blood during cancer immunotherapyXiyu Peng, Jasme Lee, Matthew Adamow, et al.
Cancers|May 14, 2025
Natural Language Processing of Radiology Reports to Assess Survival in Patients with Advanced MelanomaJeeban P Das, Jordan Eichholz, Varadan Sevilimedu, et al.
Cancer Treatment Reviews|July 10, 2017
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their managementMario Sznol, Michael A Postow, Marianne J Davies, et al.
Ebiomedicine|March 31, 2017
Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab TreatmentMichael R Cassidy, Rachel E Wolchok, Junting Zheng, et al.
Journal for Immunotherapy of Cancer|October 18, 2017
Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatmentErik S Anderson, Michael A Postow, Jedd D Wolchok, et al.
CNS Oncology|February 21, 2023
Efficacy of immunotherapy for melanoma brain metastases in patients with concurrent corticosteroid exposureKathryn R Tringale, Anne S Reiner, Ryka R Sehgal, et al.
Cancer Immunology Research|April 30, 2014
Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanomaChristopher A Barker, Michael A Postow, Shaheer A Khan, et al.
Annals of Surgical Oncology|March 18, 2017
Elevated Blood Neutrophil-to-Lymphocyte Ratio: A Readily Available Biomarker Associated with Death due to Disease in High Risk Nonmetastatic MelanomaJeremy L Davis, Russell C Langan, Katherine S Panageas, et al.
Cancer|March 2, 2021
Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapiesEvan D Bander, Melissa Yuan, Joseph A Carnevale, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Pre-treatment naïve T cells are associated with severe irAE following PD-1/CTLA4 checkpoint blockade for melanomaKathryne E Marks, Alice Horisberger, Mehreen Elahee, et al.
Pageof 22

Showing results (71-80 of 212) with videos related to

Sort By:
Pageof 22
Cell Reports Methods|September 6, 2023
A topic modeling approach reveals the dynamic T cell composition of peripheral blood during cancer immunotherapyXiyu Peng, Jasme Lee, Matthew Adamow, et al.
Cancers|May 14, 2025
Natural Language Processing of Radiology Reports to Assess Survival in Patients with Advanced MelanomaJeeban P Das, Jordan Eichholz, Varadan Sevilimedu, et al.
Cancer Treatment Reviews|July 10, 2017
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their managementMario Sznol, Michael A Postow, Marianne J Davies, et al.
Ebiomedicine|March 31, 2017
Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab TreatmentMichael R Cassidy, Rachel E Wolchok, Junting Zheng, et al.
Journal for Immunotherapy of Cancer|October 18, 2017
Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatmentErik S Anderson, Michael A Postow, Jedd D Wolchok, et al.
CNS Oncology|February 21, 2023
Efficacy of immunotherapy for melanoma brain metastases in patients with concurrent corticosteroid exposureKathryn R Tringale, Anne S Reiner, Ryka R Sehgal, et al.
Cancer Immunology Research|April 30, 2014
Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanomaChristopher A Barker, Michael A Postow, Shaheer A Khan, et al.
Annals of Surgical Oncology|March 18, 2017
Elevated Blood Neutrophil-to-Lymphocyte Ratio: A Readily Available Biomarker Associated with Death due to Disease in High Risk Nonmetastatic MelanomaJeremy L Davis, Russell C Langan, Katherine S Panageas, et al.
Cancer|March 2, 2021
Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapiesEvan D Bander, Melissa Yuan, Joseph A Carnevale, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Pre-treatment naïve T cells are associated with severe irAE following PD-1/CTLA4 checkpoint blockade for melanomaKathryne E Marks, Alice Horisberger, Mehreen Elahee, et al.
Pageof 22